Depression medication study for adults 19 to 65
Part of Mental health clinical trials.
This study tests a new way of choosing antidepressants for people with major depression. It's designed for adults aged 19–65 who have moderate to severe depression and are either starting a new antidepressant or have been off psychiatric meds for at least a month.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 19 and 65 years old.
- You must have a diagnosis of major depression (not bipolar or other mood disorder) and a depression severity score of at least 17 on the Hamilton Rating Scale.
- You can either start a new antidepressant for this depression or not have taken any psychiatric meds (except sleep aids or benzodiazepines) in the past month.
- You cannot have other mental health conditions like bipolar disorder, schizophrenia, psychosis, eating disorder, or obsessive-compulsive disorder.
- You cannot have epilepsy, seizures, or unstable medical problems, and must not be at high risk of suicide or harming yourself or others.
- You must be able to understand the study and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a personalized combination of talk therapy (CBT) and antidepressant medication works better for people with moderate to severe depression. It’s meant to match treatment choices to your situation and to see what helps most.
This study tests a new medication called BMS-986511 for adults with major depressive disorder. It aims to see if the drug can help relieve depression symptoms more effectively than a placebo.
This Phase 4 study tests an “optimized” medication approach for adults with major depressive disorder (unipolar depression) based on how you respond over time. It may help your care team choose treatments more effectively and reduce trial-and-error.
This Phase 2 trial tests whether an NMDA-targeted treatment can improve symptoms of major depressive disorder (MDD). You may be able to join if your depression diagnosis and symptom score fit, and you meet several safety and study-following requirements.
This trial tests a personalized approach to treating major depressive disorder using assessments and brain imaging to match you with the best therapy. It aims to improve outcomes by tailoring care to your specific needs.
This study tests an investigational drug called KH607 for adults with major depressive disorder (MDD). It aims to see if the drug can reduce depression symptoms over time. Participants must stop other depression medications before starting and will be monitored closely.
Hear when a new Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.